Last reviewed · How we verify

NCT05394324

A Post-market Clinical Study to Collect Safety and Performance Data on Johnson & Johnson Surgical Vision Products

Completed Last updated 20 July 2025
What this trial tests

trial testing Intervention in Refractive Error in 1,674 participants. Completed in 31 May 2025.

Timeline
21 June 2022
Primary endpoint
31 May 2025
31 May 2025

Quick facts

Lead sponsorJohnson & Johnson Surgical Vision, Inc.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,674
Start date21 June 2022
Primary completion31 May 2025
Estimated completion31 May 2025
Sites13 locations across United States, Germany, Spain

Drugs / interventions tested

Conditions studied

Sponsor

Johnson & Johnson Surgical Vision, Inc. — full company profile →

Who can join

Eligibility, any sex, with Refractive Error or Glaucoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retrospective collection of data from medical records, multicenter, post-market clinical follow-up study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Intervention

Trials testing the same drug.

Other recruiting trials for Refractive Error

Currently open trials in the same condition.

Other Johnson & Johnson Surgical Vision, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05394324.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing